Hatta, Yoshihiro http://orcid.org/0000-0002-0457-4015
Mizuta, Shuichi
Matsuo, Keitaro
Ohtake, Shigeki
Iwanaga, Masako
Sugiura, Isamu
Doki, Noriko
Kanamori, Heiwa
Ueda, Yasunori
Yoshida, Chikamasa
Dobashi, Nobuaki
Maeda, Tomoya
Yujiri, Toshiaki
Monma, Fumihiko
Ito, Yoshikazu
Hayakawa, Fumihiko
Takeuchi, Jin
Kiyoi, Hitoshi
Miyazaki, Yasushi
Naoe, Tomoki
Funding for this research was provided by:
Health and Labor Sciences Research Grant (MHLW KAKENHI H26-Kakushintekigan-Ippan-133)
Article History
Received: 26 July 2017
Accepted: 31 March 2018
First Online: 24 April 2018
Compliance with ethical standards
: All protocols were approved by JALSG and subsequently reviewed by the institutional review board of each participating center.
: YH received honoraria from Novartis, Kyowa-Hakko Kirin, and Chugai Pharmaceutical. YT received honoraria from Novartis. YM received honoraria and research funding from Novartis. TN received research funding or patents and royalties from Astellas Pharma, Celgene, Kyowa-Hakko Kirin, Nippon Boehringer Ingelheim, Otsuka Pharmaceutical, Pfizer, Toyama Chemical, and Chugai Pharmaceutical. Imatinib was provided by Novartis Pharma.
: Informed consent was obtained from all patients for being included in the study.